Ashley Kalinauskas is Chief Executive Officer & Co-Founder of Torigen Pharmaceuticals, a company that is focused on personalized cancer immunotherapy for the veterinary market. Recently, Ashley was named to the highly coveted 2020 Forbes 30 under 30 list. Ashley graduated from the University of Connecticut with an undergraduate degree in Pathobiology, and continued her studies at the University of Notre Dame with a master’s degree in Engineering, Science, and Technology Entrepreneurship. Her education provided her with the business skills necessary to translate inventions into commercial ventures, like Torigen! This start-up company resulted from her graduate thesis project, and is based upon the research of her former University of Notre Dame professor, Dr. Mark Suckow. Ashley has assembled an amazing team of veterinary professionals and immuno-oncology researchers to assist her in building Torigen and evaluating new cutting edge therapies to consider folding into the company.